Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 2/20 | 0.47 |
| ▸ | CES1 | P23141 | 2/20 | 0.47 |
| ▸ | CYP1A1 | P04798 | 8/20 | 0.47 |
| ▸ | CYP1B1 | Q16678 | 8/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | P4HB | P07237 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL970479 | 0.85 | CYP1A1 (0.46) | NR4A1NR4A2NR4A3CES2CES1 | |
| SCHEMBL970477 | 0.85 | CYP1A1 (0.46) | NR4A1NR4A2NR4A3CES2CES1 | |
| SCHEMBL2271846 | 0.81 | NR4A1 (0.57) | NR4A1NR4A2NR4A3CES2CES1 | |
| SCHEMBL2271850 | 0.81 | NR4A1 (0.57) | NR4A1NR4A2NR4A3CES2CES1 | |
| SCHEMBL10038015 | 0.80 | ALDH1A1 (0.53) | CES2CES1CYP1B1MAOB | |
| SCHEMBL10073423 | 0.75 | CYP1A1 (0.51) | NR4A1NR4A2NR4A3CES2CES1 | |
| SCHEMBL9619495 | 0.75 | MAPT (0.66) | NR4A1NR4A2NR4A3CES2CES1 | |
| SCHEMBL29089422 | 0.74 | CYP1A1 (0.56) | NR4A1NR4A2NR4A3CES2CES1 | |
| SCHEMBL11625967 | 0.74 | CES2 (0.55) | NR4A1NR4A2NR4A3CES2CES1 | |
| SCHEMBL13864065 | 0.74 | NFE2L2 (0.59) | NR4A1NR4A2NR4A3CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142728-A1 | CHEMICAL COMPOUND AND ITS USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-07 | — | — | US | disclosed |
| US-8124775-B2 | Tetrahydroquinoline compound; cardiovascular disorders; arteriosclerosis | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-28 | — | — | US | disclosed |
| US-8124775-B2 | Tetrahydroquinoline compound; cardiovascular disorders; arteriosclerosis | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-28 | — | — | US | disclosed |
| US-20080255068-A1 | Tetrahydroquinoline compound; cardiovascular disorders; arteriosclerosis | BAYER HEALTHCARE AG (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255068-A1 | Tetrahydroquinoline compound; cardiovascular disorders; arteriosclerosis | BAYER HEALTHCARE AG (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080194609-A1 | Chemical Compound and Its Use | BAYER HEATHCARE AG (DE) | 2008-08-14 | — | — | US | disclosed |
| US-20080194609-A1 | Chemical Compound and Its Use | BAYER HEATHCARE AG (DE) | 2008-08-14 | — | — | US | disclosed |
| US-20050043341-A1 | 3-'Hydroxy-(-4-trifluoromethylphenyl)-methyl-7-spirocyclobutyl-5,6,7 8-tetrahydroquinolin-5-ol derivatives and the use of the same as cholesterol ester transfer protein (cetp) inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043341-A1 | 3-'Hydroxy-(-4-trifluoromethylphenyl)-methyl-7-spirocyclobutyl-5,6,7 8-tetrahydroquinolin-5-ol derivatives and the use of the same as cholesterol ester transfer protein (cetp) inhibitors | CETP, MTTP, HDLBP | NR4A1 352/4885NR4A2 328/4885NR4A3 238/4885 |
| US-20120142728-A1 | CHEMICAL COMPOUND AND ITS USE | CETP, MTTP, LCAT | NR4A1 1553/4885NR4A2 1084/4885NR4A3 1300/4885 |
| US-20080255068-A1 | Tetrahydroquinoline compound; cardiovascular disorders; arteriosclerosis | CETP, MTTP, HDLBP | NR4A1 1259/4885NR4A2 938/4885NR4A3 1037/4885 |
| US-20080194609-A1 | Chemical Compound and Its Use | CETP, MTTP, LCAT | NR4A1 1089/4885NR4A2 830/4885NR4A3 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.